|
|
Post by agedhippie on Mar 2, 2022 12:36:57 GMT -5
Impressive research of the board archives. if a person were to keep looking or searching Matt's posts, the months and year Matt predicted MNKD would go bankrupt could be found. Both Matt and agedhippie left the board after the UTHR deal. Matt's market knowledge superior. He knew all the books and were the words were located. Then came the day, Matt talked about intubation. I still lurk, but my interest is really in Afrezza rather than the stock and since that doesn't really look like MNKD's direction it sort of kills the point for me. For the record - I don't see the FDA delay as serious, just annoying. It's not like MNKD will run out of money before May, and I would be extremely surprised if it was rejected. |
|
|
|
Post by cretin11 on Mar 2, 2022 13:07:21 GMT -5
aged good to see you. Totally understand where you're coming from on MNKD's apparent direction with Afrezza, but hopefully that's a temporary situation. VDEX and Bill are not throwing in the towel on it. I agree with your take on the FDA delay, fingers crossed.
|
|
|
|
Post by peppy on Mar 2, 2022 13:14:15 GMT -5
If I were Mike I would be calling Joshua Davis today and I would try and get him into the kids trial. TV commercials with Joshua demonstrating "Seeing is Believing" as a T1 in the trial and saying Mannkind has insulin for $99 a month might get some attention. This! That is a great idea and an obvious golden opportunity for much needed PR and positive attention. It should happen today. "Joshua Davis has Type 1 diabetes Davis, who is from Midlothian, Virginia, was diagnosed with Type 1 diabetes when he was just 11 months old, according to the White House. At the age of 4, Davis began advocating for the Virginia General Assembly to make "school safer for kids with Type 1 diabetes." Since then, Davis has continued to raise awareness, advocating for lowering the costs of insulin and prescription drug costs, alongside his father, Brian, who also has Type 1 diabetes. " www.usatoday.com/story/news/politics/2022/03/01/joshua-davis-state-of-union-insulin-prices/9336507002/ |
|
|
|
Post by peppy on Mar 2, 2022 13:15:04 GMT -5
if a person were to keep looking or searching Matt's posts, the months and year Matt predicted MNKD would go bankrupt could be found. Both Matt and agedhippie left the board after the UTHR deal. Matt's market knowledge superior. He knew all the books and were the words were located. Then came the day, Matt talked about intubation. I still lurk, but my interest is really in Afrezza rather than the stock and since that doesn't really look like MNKD's direction it sort of kills the point for me. For the record - I don't see the FDA delay as serious, just annoying. It's not like MNKD will run out of money before May, and I would be extremely surprised if it was rejected. Love you too. Thanks for the post. |
|
|
|
Post by sayhey24 on Mar 2, 2022 14:03:20 GMT -5
if a person were to keep looking or searching Matt's posts, the months and year Matt predicted MNKD would go bankrupt could be found. Both Matt and agedhippie left the board after the UTHR deal. Matt's market knowledge superior. He knew all the books and were the words were located. Then came the day, Matt talked about intubation. I still lurk, but my interest is really in Afrezza rather than the stock and since that doesn't really look like MNKD's direction it sort of kills the point for me. For the record - I don't see the FDA delay as serious, just annoying. It's not like MNKD will run out of money before May, and I would be extremely surprised if it was rejected. Aged - what interest is it you have in afrezza? I am assuming you still have not tried it. Mike is expanding his "Seeing is Believing" campaign which I hope will have some good success. |
|
|
|
Post by rombic33 on Mar 2, 2022 15:32:57 GMT -5
Not to sound too pessimistic, but I heard that the stock market is a device for transferring money from the most of the people most of the time. Or short sellers don’t exist?
|
|
|
|
Post by Clement on Mar 2, 2022 19:06:08 GMT -5
The stock market is a device for transfering money from the impatient to the patient.
That's attributed to Warren Buffett.
|
|
|
|
Post by peppy on Mar 2, 2022 19:24:43 GMT -5
The stock market is a device for transfering money from the impatient to the patient. That's attributed to Warren Buffett. another tag line. Remember Blackberry? I think it is gone. remember Sears, Roebuck and Co.? The indices, can change members. The Dow has. |
|
|
|
Post by agedhippie on Mar 2, 2022 19:26:18 GMT -5
I still lurk, but my interest is really in Afrezza rather than the stock and since that doesn't really look like MNKD's direction it sort of kills the point for me. For the record - I don't see the FDA delay as serious, just annoying. It's not like MNKD will run out of money before May, and I would be extremely surprised if it was rejected. Aged - what interest is it you have in afrezza? I am assuming you still have not tried it. Mike is expanding his "Seeing is Believing" campaign which I hope will have some good success. Same interest as I have always had: I want as many options as possible for diabetics. No, I still haven't tried it although I am edging closer as I periodically have absorption issues that I think it would help with. I am not convinced that "Seeing is Believing" will move the needle because of the SoC for Type 2. A PCP is going to follow the SoC since it's not his specialty and this covers them against liability suits. Typically a PCP will push a patient to an endo at the first sign of MDI, or possibly earlier, because they don't feel confident with insulin so why take the risk? It takes a clinic like VDex that already believe in Afrezza to do what Mike wants, and he is explicitly excluding them! There is no secret here. If Mike wants adoption the answer is the same as it has been for the last seven years - a large scale multi-arm superiority trial. Absent that expect more of the same growth because there is no incentive for the endos to switch, nor insurers to cover Afrezza (actually, how is coverage going since I haven't looked for a while?) |
|
|
|
Post by sayhey24 on Mar 3, 2022 13:53:48 GMT -5
Aged - what interest is it you have in afrezza? I am assuming you still have not tried it. Mike is expanding his "Seeing is Believing" campaign which I hope will have some good success. Same interest as I have always had: I want as many options as possible for diabetics. No, I still haven't tried it although I am edging closer as I periodically have absorption issues that I think it would help with. I am not convinced that "Seeing is Believing" will move the needle because of the SoC for Type 2. A PCP is going to follow the SoC since it's not his specialty and this covers them against liability suits. Typically a PCP will push a patient to an endo at the first sign of MDI, or possibly earlier, because they don't feel confident with insulin so why take the risk? It takes a clinic like VDex that already believe in Afrezza to do what Mike wants, and he is explicitly excluding them! There is no secret here. If Mike wants adoption the answer is the same as it has been for the last seven years - a large scale multi-arm superiority trial. Absent that expect more of the same growth because there is no incentive for the endos to switch, nor insurers to cover Afrezza (actually, how is coverage going since I haven't looked for a while?) I think we are going to agree to disagree on the large scale study moving the needle. I hope I am wrong as they are doing the India study but I have lost most faith in the ADA. There is too much money and the last thing BP wants is afrezza showing up as step 1 or 2 in the SoC. Its not happening. I have hope for "Seeing is Believing" more so than a large study if Mike can start getting some large corp GP organizations believing. The SoC would be replaced by the corporate protocal in these practice which control many GPs. He has a chance and hope springs external. What we have seen over the last few years is as we predicted a few years back, the CGM is changing how diabetes is treated. Now its time to do more than monitor, its time to stop the post prandial spike and get these T2s back to baseline in under 2 hours. If you are still thinking about trying afrezza yourself, there was an offer from Bill from VDex about a month ago to give it a try under VDex's supervisor. I am sure with a little arm twisting Bill would extend the offer to you and I am sure there would be many interested folks on this board and beyond to see how afrezza works for you. What do you think? Is now the time? |
|
|
|
Post by peppy on Mar 4, 2022 6:15:18 GMT -5
Aged - what interest is it you have in afrezza? I am assuming you still have not tried it. Mike is expanding his "Seeing is Believing" campaign which I hope will have some good success. Same interest as I have always had: I want as many options as possible for diabetics. No, I still haven't tried it although I am edging closer as I periodically have absorption issues that I think it would help with. I am not convinced that "Seeing is Believing" will move the needle because of the SoC for Type 2. A PCP is going to follow the SoC since it's not his specialty and this covers them against liability suits. Typically a PCP will push a patient to an endo at the first sign of MDI, or possibly earlier, because they don't feel confident with insulin so why take the risk? It takes a clinic like VDex that already believe in Afrezza to do what Mike wants, and he is explicitly excluding them! There is no secret here. If Mike wants adoption the answer is the same as it has been for the last seven years - a large scale multi-arm superiority trial. Absent that expect more of the same growth because there is no incentive for the endos to switch, nor insurers to cover Afrezza (actually, how is coverage going since I haven't looked for a while?) Oh aged, I know I should leave you alone, however, your words, "I periodically have absorption issues that I think it would help with." This is new. Do you want me to fix it for you? Your blood glucose levels have been out of wack? You are thinking you might try afrezza to bring your blood glucose down? alrighty then. Report back and allow us to know. One more thing, just asking. Does andropause affect subq insulin absorption? Asking for a friend.  |
|
|
|
Post by sayhey24 on Mar 7, 2022 11:08:36 GMT -5
Peppy - did we scare Aged away???
|
|
|
|
Post by peppy on Mar 7, 2022 11:19:42 GMT -5
Peppy - did we scare Aged away??? heh. Aged has found other interests I guess. I thinks he comes to check on us because we are so fun as in amusing. |
|
|
|
Post by sayhey24 on Mar 7, 2022 14:44:50 GMT -5
Peppy - did we scare Aged away??? heh. Aged has found other interests I guess. I thinks he comes to check on us because we are so fun as in amusing. I hope he checks back soon. We never heard from Stanley again. I hope we are fun. I think I am more strange than fun. I think looking at AGPs is fun and that can't be normal. Looking at Aged's AGPs once he is on afrezza would be like a party. |
|
|
|
Post by lakers on Mar 7, 2022 15:48:01 GMT -5
Trade Alert: The Independent Director Of MannKind Corporation (NASDAQ:MNKD), Jennifer Grancio, Has Just Spent US$300k Buying 83% More Shares
Simply Wall St
March 7, 2022, 2:59 am
Potential MannKind Corporation (NASDAQ:MNKD) shareholders may wish to note that the Independent Director, Jennifer Grancio, recently bought US$300k worth of stock, paying US$2.71 for each share. We reckon that's a good sign, especially since the purchase boosted their holding by 83%.
Notably, that recent purchase by Jennifer Grancio is the biggest insider purchase of MannKind shares that we've seen in the last year. That means that an insider was happy to buy shares at around the current price of US$3.00. That means they have been optimistic about the company in the past, though they may have changed their mind. If someone buys shares at well below current prices, it's a good sign on balance, but keep in mind they may no longer see value. In this case we're pleased to report that the insider purchases were made at close to current prices.
While MannKind insiders bought shares during the last year, they didn't sell.
|
|
